Please login to the form below
Healthcare Glossary
A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W |
Shareholder value
Shareholder Value is the appreciation that a shareholder obtains from his/her investment in a company. This may consist of capital gains, dividend payments, profits from buyback programs and other payments a firm might make to a shareholder.
See also:
Stakeholder
Related terms
Health Maintenance Organisation (HMO), Non-profit marketing, Cost-effective (healthcare economics), Frequency, Cost-effectiveness threshold (health economics), Product class, Growth stage, Added value, Customer lifetime value (CLV), Competitor analysis, Discounted cash flow (DCF), Brand mapping , Corporate governance, Market forecast, Moving annual total (MAT),
COVID-19 Updates and Daily News
Featured jobs
-
Head of Copy
-
£ competitive
- Pfizer CEO announces plans to launch Omicron-specific COVID-19 vaccine
- Sanofi and Exscientia agree on a deal worth up to $5.2bn for AI-driven therapies
- Biogen’s Alzheimer’s treatment Aduhelm limited to clinical trial participants in the US
- Pfizer expands access to lipid nanoparticle technology in new agreement with Acuitas Therapeutics
- BioNTech and InstaDeep collaboration develops SARS-CoV-2 Early Warning System
- BMS and Century Therapeutics agree on deal potentially worth over $3bn
- Live Webinar: Measuring Vital Health Indicators Through Your Camera
- AstraZeneca's Enhertu receives FDA grant for priority review
- Pfizer’s Cibinqo granted FDA approval for adults with moderate-to-severe atopic dermatitis
- Julie Beeso joins Envision Pharma Group in new Global Director, Professional Development and Engagement role
- Live Webinar: Expanding Access to High-Quality Healthcare
- Vir Biotech launches new research programme for HIV and malaria prevention
- Sanofi and Exscientia agree on a deal worth up to $5.2bn for AI-driven therapies
- Why pharma must get smart in its approach to customer engagement
- NAVIGATING 2022: THE FIVE CRITICAL SHIFTS PHARMA NEEDS TO EMBRACE
- Amgen’s Lumykras receives conditional marketing authorisation from EC
- BMS and Century Therapeutics agree on deal potentially worth over $3bn
- FDA nod for Janssen schizophrenia treatment Invega Hafyera
